Repaglinide Loaded Hybrid Nanocarrier for the Management of Diabetes Mellitus Induced Neuronal Complications

Abstract

Diabetes mellitus is a complicated metabolic disorder associated with various vascular complications, and these complications lead to co-morbid diseases such as Alzheimer's. Repaglinide, inhibits the ATP-sensitive potassium channel and stimulates the release of insulin. It targets downstream regulatory element antagonist modulator and regulates the potassium-calcium channels homeostasis. In this present study, a novel self-assembled lipid polymer-based nanocarrier system for repaglinide has been developed. The developed formulation has good pharmacokinetic profile which will help in reduction of dose and dose frequency. Hence, it may lead to better patient compliance.